ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial
Research output: Contribution to journal › Journal article › Research › peer-review
Excision repair cross complementation group 1 (ERCC1) is a promising biomarker in advanced non-small cell lung cancer (NSCLC). However, current evidence regarding the impact of ERCC1 on toxicity and quality of life (QOL) is limited.
| Original language | English |
|---|---|
| Journal | European Journal of Cancer |
| Volume | 46 |
| Issue number | 9 |
| Pages (from-to) | 1554-62 |
| Number of pages | 9 |
| ISSN | 0959-8049 |
| DOIs | |
| Publication status | Published - 1 Jun 2010 |
ID: 34096524